Rajinder Singh

发表

A class of small molecules that inhibit TNFalpha-induced survival and death pathways via prevention of interactions between TNFalphaRI, TRADD, and RIP1.

D. Payan, E. Masuda, T. Kinoshita, 2007, Chemistry & biology.

A Class of Small Molecules that Inhibit TNFα-Induced Survival and Death Pathways via Prevention of Interactions between TNFαRI, TRADD, and RIP1

Donald G. Payan, Jianing Huang, D. Payan, 2007 .

Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology Agent.

J. Fargnoli, S. Sheriff, A. Mathur, 2020, ACS medicinal chemistry letters.

Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen

V. Markovtsov, C. Low, Y. Hitoshi, 2009, Journal of Cancer Research and Clinical Oncology.

R-253 Disrupts Microtubule Networks in Multiple Tumor Cell Lines

Y. Hitoshi, D. Payan, E. Pali, 2006, Clinical Cancer Research.

diaphragmced protease activation in the Oxidative stress is required for mechanical

S. Powers, L. Koch, S. Britton, 2015 .

Inhibition of Janus kinase signaling during controlled mechanical ventilation prevents ventilation-induced diaphragm dysfunction

S. Powers, Ira J. Smith, D. Payan, 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Chapter 24 Spleen Tyrosine Kinase (Syk) Biology, Inhibitors and Therapeutic Applications

E. Masuda, Rajinder Singh, 2007 .

CC chemokine receptor 2 promotes recruitment of myeloid cells associated with insulin resistance in nonalcoholic fatty liver disease.

James J. Campbell, C. Weston, D. Adams, 2018, American journal of physiology. Gastrointestinal and liver physiology.

Identification of the Syk kinase inhibitor R112 by a human mast cell screen.

D. Payan, E. Masuda, Rajinder Singh, 2006, The Journal of allergy and clinical immunology.

IL-17–Secreting γδ T Cells Are Completely Dependent upon CCR6 for Homing to Inflamed Skin

James J. Campbell, T. Schall, I. Charo, 2017, The Journal of Immunology.

CC Chemokine Receptor 2 Promotes 1 Recruitment of Myeloid Cells Associated with 2 Insulin Resistance in Non-Alcoholic Fatty Liver 3 Disease 4

James J. Campbell, C. Weston, D. Adams, 2018 .

Structure activity relationships leading to the identification of the indirect activator of AMPK, R419.

V. Markovtsov, Y. Hitoshi, D. Payan, 2022, Bioorganic & medicinal chemistry.

A small molecule CCR2 antagonist depletes tumor macrophages and synergizes with anti-PD1 in a murine model of cutaneous T cell lymphoma (CTCL).

James J. Campbell, D. Hsu, Dan Han, 2020, The Journal of investigative dermatology.

Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts.

S. Sleijfer, A. Hezel, T. Schall, 2018 .

Abstract 5655: Inhibition of CCR2 potentiates checkpoint inhibitor immunotherapy in murine model of pancreatic cancer

T. Schall, I. Charo, Rajinder Singh, 2017 .

Discovery and Characterization of Substituted Diphenyl Heterocyclic Compounds as Potent and Selective Inhibitors of Hepatitis C Virus Replication (cid:1)

D. Payan, K. Qu, T. Kinsella, 2008 .

The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma

E. Montgomery, G. Riggins, J. Eshleman, 2010, Cancer biology & therapy.

CCR2 antagonism leads to marked reduction in proteinuria and glomerular injury in murine models of focal segmental glomerulosclerosis (FSGS)

James J. Campbell, T. Schall, I. Charo, 2018, PloS one.

A one-pot synthesis of tetrazolones from acid chlorides: understanding functional group compatibility, and application to the late-stage functionalization of marketed drugs.

Rajinder Singh, M. Duncton, 2016, Organic & biomolecular chemistry.

CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas

R. Jain, T. Schall, Meenal Datta, 2019, Proceedings of the National Academy of Sciences.

Discovery and development of spleen tyrosine kinase (SYK) inhibitors.

D. Payan, E. Masuda, Rajinder Singh, 2012, Journal of medicinal chemistry.

Efficacy of Chemokine Receptor Inhibition in Treating IL-36α–Induced Psoriasiform Inflammation

T. Schall, I. Charo, Rajinder Singh, 2019, The Journal of Immunology.

R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation

D. Payan, Haoran Zhao, K. Qu, 2006, Journal of Pharmacology and Experimental Therapeutics.

Cancer associated fibroblast FAK regulates malignant cell metabolism

T. Schall, T. Graham, F. Balkwill, 2020, Nature Communications.

R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm.

Takuya Matsunaga, Gary Park, Wayne Lang, 2011, Blood.

Design, synthesis of diaminopyrimidine inhibitors targeting IgE- and IgG-mediated activation of Fc receptor signaling.

D. Payan, Haoran Zhao, E. Masuda, 2015, Bioorganic & medicinal chemistry letters.

Identification of Mycobacterium tuberculosis genes preferentially expressed during human infection.

D. Chauhan, Rahul Sharma, I. Khan, 2011, Microbial pathogenesis.

CCR2-Mediated Uptake of Constitutively Produced CCL2: A Mechanism for Regulating Chemokine Levels in the Blood

T. Schall, T. Handel, I. Kufareva, 2019, The Journal of Immunology.

R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.

Y. Hitoshi, D. Payan, Weiqun Li, 2010, Cancer research.

R 428 , a Selective Small Molecule Inhibitor of Axl Kinase , Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer

Y. Hitoshi, D. Payan, Weiqun Li, 2010 .

Developing DYRK inhibitors derived from the meridianins as a means of increasing levels of NFAT in the nucleus.

D. Payan, T. Kinsella, J. McLaughlin, 2017, Bioorganic & medicinal chemistry letters.

Cancer Burden Is Controlled by Mural Cell-β3-Integrin Regulated Crosstalk with Tumor Cells

J. Gribben, T. Schall, P. Szlosarek, 2020, Cell.

Optimization of Pyrimidine Compounds as Potent JAK1 Inhibitors and the Discovery of R507 as a Clinical Candidate.

D. Payan, E. Masuda, Hui Li, 2022, ACS Medicinal Chemistry Letters.

AMPK Activation through Mitochondrial Regulation Results in Increased Substrate Oxidation and Improved Metabolic Parameters in Models of Diabetes

B. Viollet, V. Markovtsov, L. Boros, 2013, PloS one.

Orally administered CCR2 selective inhibitor CCX872-b clinical trial in pancreatic cancer.

S. Sleijfer, A. Hezel, T. Schall, 2017 .

Developing structure-activity relationships from an HTS hit for inhibition of the Cks1-Skp2 protein-protein interaction.

D. Payan, L. Tsvetkov, Jianing Huang, 2015, Bioorganic & medicinal chemistry letters.

Tetrazolone as an acid bioisostere: application to marketed drugs containing a carboxylic acid.

Rajinder Singh, G. Park, M. Duncton, 2016, Organic & biomolecular chemistry.

Selective Small Molecule Inhibitor of Axl Kinase , Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer

Y. Hitoshi, D. Payan, Weiqun Li, 2010 .

Bicyclic pyrimidine compounds as potent IRAK4 inhibitors.

D. Payan, E. Masuda, Hui Li, 2022, Bioorganic & medicinal chemistry letters.

Cancer associated fibroblast FAK regulates malignant cell metabolism

T. Schall, T. Graham, F. Balkwill, 2020, Nature Communications.

Global metabolite profiling of mice with high-fat diet-induced obesity chronically treated with AMPK activators R118 or metformin reveals tissue-selective alterations in metabolic pathways

V. Markovtsov, Y. Hitoshi, D. Payan, 2014, BMC Research Notes.

Discovery and development of spleen tyrosine kinase (SYK) inhibitors.

D. Payan, E. Masuda, Rajinder Singh, 2012, Journal of medicinal chemistry.

Application of cultured human mast cells (CHMC) for the design and structure-activity relationship of IgE-mediated mast cell activation inhibitors.

D. Payan, E. Masuda, Hui Li, 2015, Bioorganic & medicinal chemistry letters.

In Vitro and in Vivo Inhibition of JAK2 Signaling by Potent and Selective JAK2 Inhibitor

V. Markovtsov, C. Low, Y. Hitoshi, 2008 .

Developing structure-activity relationships from an HTS hit for inhibition of the Cks1-Skp2 protein-protein interaction.

D. Payan, L. Tsvetkov, Jianing Huang, 2015, Bioorganic & medicinal chemistry letters.